Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Health Assurance Acquisition Corp.HAAC · Entity 122106 | Director | November 12, 2020 | November 13, 2020 |
| Revolution Healthcare Acquisition Corp.REVH · Entity 135631 | Director | March 17, 2021 | March 17, 2021 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | May 01, 2026 | May 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Health Assurance Acquisition Corp.
Report date November 12, 2020 · Filed November 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B common stockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-11-12 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249667), as amended, under the heading "Description of Securities-Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the issuer after the consummation of the issuer's initial business combination. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249667), as amended, under the heading "Description of Securities-Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the issuer after the consummation of the issuer's initial business combination.
Revolution Healthcare Acquisition Corp.
Report date March 17, 2021 · Filed March 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B common stockSEC Table I · non-derivative | Direct | 6,250 |
Reported balance
Holding disclosure · report date 2021-03-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 6,250 F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination.
VERTEX PHARMACEUTICALS INC / MA
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,394 |
Ending reported balance
After 2026-05-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-01 · Grant · Acquired 472 · Balance 2,190 F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Row 2 · 2026-05-01 · Disposition to issuer · Disposed 796 · Balance 1,394 F2: Upon the vesting of restricted stock units granted to Dr. Schneider on May 1, 2025, Dr. Schneider deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Dr. Schneider is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $424.45 · Expires 2036-04-30 | Direct | 1,433 |
Reported balance
After 2026-05-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-01 · Grant · Acquired 1,433 · Balance 1,433 F3: Fully vested. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 796 |
Reported balance
After 2026-05-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-01 · Grant · Acquired 796 · Balance 796 F4: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Schneider's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Schneider's disability or death. F2: Upon the vesting of restricted stock units granted to Dr. Schneider on May 1, 2025, Dr. Schneider deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Dr. Schneider is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
F2: Upon the vesting of restricted stock units granted to Dr. Schneider on May 1, 2025, Dr. Schneider deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Dr. Schneider is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.
F3: Fully vested.
F4: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Schneider's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Schneider's disability or death.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Livongo Health, Inc.
Report date October 30, 2020 · Filed October 30, 2020
Section 16 reporting ended · disclosed 2020-10-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 1
1 source rowRow 1 · 2020-10-30 · Disposition to issuer · Disposed 208,387 · Balance 0 F1: Includes 197,304 restricted stock units ("RSUs"). F2: Includes 210 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on October 28, 2020. F3: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F4: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F5: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2025-09-02 | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-30 · Disposition to issuer · Disposed 524,602 · Balance 0 F5: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F7: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F6: Shares subject to the option are fully vested and immediately exercisable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.38 · Expires 2026-11-15 | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-30 · Disposition to issuer · Disposed 80,000 · Balance 0 F5: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F7: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F8: One-fourth of the shares subject to the option vested on November 16, 2017 and 1/48 of the shares vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2028-06-18 | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-30 · Disposition to issuer · Disposed 150,000 · Balance 0 F5: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F7: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F9: One-fourth of the shares subject to the option vested on June 19, 2019 and 1/48 of the shares vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 197,304 restricted stock units ("RSUs").
F2: Includes 210 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on October 28, 2020.
F3: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any).
F4: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions).
F5: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020.
F6: Shares subject to the option are fully vested and immediately exercisable.
F7: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions).
F8: One-fourth of the shares subject to the option vested on November 16, 2017 and 1/48 of the shares vest monthly thereafter.
F9: One-fourth of the shares subject to the option vested on June 19, 2019 and 1/48 of the shares vest monthly thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2020 Filed May 18, 2020 22:52 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 517 | $59.32 | $30,668.44 |
DisclosureSEC source: 0001209191-20-030237 · doc4.xml · nonDerivative · entry 2 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,668 F2 · shares: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of RSUs. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:52 UTC | Livongo Health, Inc. LVGO · Entity 145566 | GrantCommon Stock | 69,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030237 · doc4.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,185 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in 16 equal quarterly installments beginning on August 25, 2020. Read SEC document |
| May 04, 2020 Filed May 5, 2020 20:12 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,700 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-20-027075 · doc4.xml · derivative · entry 6 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618,083 Underlying: Common Stock · 6,700 shares Expires 2025-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F4 · derivative.exercise_date: One-fourth of the shares subject to the option vested on September 1, 2016 and 1/48 of the shares vest monthly thereafter. Read SEC document |
| May 04, 2020 Filed May 5, 2020 20:12 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 6,700 | $38.04 | $254,874.03 |
DisclosureSEC source: 0001209191-20-027075 · doc4.xml · nonDerivative · entry 4 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,162 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.83 to $38.49, inclusive. Read SEC document |
| May 04, 2020 Filed May 5, 2020 20:12 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionCommon Stock | 6,700 | $0.80 | $5,360.00 |
DisclosureSEC source: 0001209191-20-027075 · doc4.xml · nonDerivative · entry 3 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:12 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,175 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-20-027075 · doc4.xml · derivative · entry 5 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 624,783 Underlying: Common Stock · 6,175 shares Expires 2025-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F4 · derivative.exercise_date: One-fourth of the shares subject to the option vested on September 1, 2016 and 1/48 of the shares vest monthly thereafter. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:12 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 6,700 | $39.01 | $261,337.52 |
DisclosureSEC source: 0001209191-20-027075 · doc4.xml · nonDerivative · entry 2 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,162 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.58 to $39.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:12 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionCommon Stock | 6,175 | $0.80 | $4,940.00 |
DisclosureSEC source: 0001209191-20-027075 · doc4.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 20:11 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 517 | $38.50 | $19,904.50 |
DisclosureSEC source: 0001209191-20-024642 · doc4.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,687 F1 · kind: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:48 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,700 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-20-023210 · doc4.xml · derivative · entry 8 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,958 Underlying: Common Stock · 6,700 shares Expires 2025-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F6 · derivative.exercise_date: One-fourth of the shares subject to the option vested on September 1, 2016 and 1/48 of the shares vest monthly thereafter. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:48 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 1,200 | $27.54 | $33,053.04 |
DisclosureSEC source: 0001209191-20-023210 · doc4.xml · nonDerivative · entry 6 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,204 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $27.60, inclusive. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:48 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 5,500 | $27.08 | $148,966.40 |
DisclosureSEC source: 0001209191-20-023210 · doc4.xml · nonDerivative · entry 5 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,404 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.40 to $27.38, inclusive. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:48 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionCommon Stock | 6,700 | $0.80 | $5,360.00 |
DisclosureSEC source: 0001209191-20-023210 · doc4.xml · nonDerivative · entry 4 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:48 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 19,677 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-20-023210 · doc4.xml · derivative · entry 7 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 637,658 Underlying: Common Stock · 19,677 shares Expires 2025-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F6 · derivative.exercise_date: One-fourth of the shares subject to the option vested on September 1, 2016 and 1/48 of the shares vest monthly thereafter. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:48 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 24,996 | $27.20 | $679,941.19 |
DisclosureSEC source: 0001209191-20-023210 · doc4.xml · nonDerivative · entry 3 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,204 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.13 to $27.39, inclusive. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:48 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 21,904 | $26.90 | $589,311.79 |
DisclosureSEC source: 0001209191-20-023210 · doc4.xml · nonDerivative · entry 2 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,200 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.12 to $27.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:48 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionCommon Stock | 19,677 | $0.80 | $15,741.60 |
DisclosureSEC source: 0001209191-20-023210 · doc4.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. Read SEC document |
| March 16, 2020 Filed Mar 17, 2020 23:43 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 361 | $20.17 | $7,281.37 |
DisclosureSEC source: 0001209191-20-019809 · doc4.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,427 F1 · kind: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:30 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 3,352 | $25.27 | $84,705.04 |
DisclosureSEC source: 0001209191-20-013018 · doc4.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,788 F1 · kind: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:27 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 361 | $26.93 | $9,721.73 |
DisclosureSEC source: 0001209191-20-010707 · doc4.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,140 F1 · kind: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| January 21, 2020 Filed Jan 24, 2020 01:53 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 4,899 | $28.90 | $141,581.10 |
DisclosureSEC source: 0001209191-20-004766 · doc4.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,501 F1 · kind: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 01:53 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionCommon Stock | 3,249 | $27.68 | $89,932.32 |
DisclosureSEC source: 0001209191-19-058926 · doc4.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 20:09 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 3,351 | $31.34 | $105,020.34 |
DisclosureSEC source: 0000899243-19-022518 · doc4.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,649 F1 · shares: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.